MX2015005266A - Nuevas variantes del receptor iib de fc gamma. - Google Patents

Nuevas variantes del receptor iib de fc gamma.

Info

Publication number
MX2015005266A
MX2015005266A MX2015005266A MX2015005266A MX2015005266A MX 2015005266 A MX2015005266 A MX 2015005266A MX 2015005266 A MX2015005266 A MX 2015005266A MX 2015005266 A MX2015005266 A MX 2015005266A MX 2015005266 A MX2015005266 A MX 2015005266A
Authority
MX
Mexico
Prior art keywords
nucleic acid
acid sequence
present
gamma receptor
vector
Prior art date
Application number
MX2015005266A
Other languages
English (en)
Other versions
MX359802B (es
Inventor
Peter Sondermann
Meer Dominik Ter
Thomas Pohl
Reno Winter
Uwe Jacob
Original Assignee
Suppremol Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suppremol Gmbh filed Critical Suppremol Gmbh
Publication of MX2015005266A publication Critical patent/MX2015005266A/es
Publication of MX359802B publication Critical patent/MX359802B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13Cyclosporins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/70535Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Abstract

La presente invención se refiere a una secuencia de ácidos nucleicos que codifica una proteína de la SEQ ID No.: 1; un vector que comprende la secuencia de ácidos nucleicos y una célula hospedera que comprende la secuencia de ácidos nucleicos o el vector. La presente invención también se refiere a una proteína obtenida u obtenible mediante la expresión de la secuencia de ácidos nucleicos o el vector en una célula hospedera. Además, la presente invención se refiere a una proteína codificada por una secuencia de ácidos nucleicos de la SEQ ID No.: 6. Adicionalmente comprendidas por la presente invención están las composiciones farmacéuticas y un método de fabricación de las mismas.
MX2015005266A 2012-10-30 2013-10-30 Nuevas variantes del receptor iib de fc gamma. MX359802B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/663,527 US10028998B2 (en) 2012-10-30 2012-10-30 Method for treating an inflammatory disease and/or an autoimmune disease with a soluble FcγRIIb
PCT/EP2013/072741 WO2014068012A1 (en) 2012-10-30 2013-10-30 Fc gamma receptor iib variants

Publications (2)

Publication Number Publication Date
MX2015005266A true MX2015005266A (es) 2015-10-26
MX359802B MX359802B (es) 2018-10-10

Family

ID=49679480

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015005266A MX359802B (es) 2012-10-30 2013-10-30 Nuevas variantes del receptor iib de fc gamma.

Country Status (28)

Country Link
US (1) US10028998B2 (es)
EP (1) EP2914624B1 (es)
JP (2) JP6423351B2 (es)
KR (1) KR102170674B1 (es)
CN (1) CN104918955B (es)
AU (1) AU2013340831B2 (es)
BR (1) BR112015008815A2 (es)
CA (1) CA2887164C (es)
CL (1) CL2015001127A1 (es)
DK (1) DK2914624T3 (es)
EA (1) EA033437B9 (es)
ES (1) ES2628049T3 (es)
HK (1) HK1209765A1 (es)
HR (1) HRP20170894T1 (es)
HU (1) HUE032786T2 (es)
IL (1) IL238528A (es)
IN (1) IN2015DN03206A (es)
LT (1) LT2914624T (es)
MX (1) MX359802B (es)
MY (1) MY173686A (es)
NZ (1) NZ706884A (es)
PH (1) PH12015500771B1 (es)
PL (1) PL2914624T3 (es)
PT (1) PT2914624T (es)
RS (1) RS56075B1 (es)
SG (1) SG11201502749VA (es)
SI (1) SI2914624T1 (es)
WO (1) WO2014068012A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10669324B2 (en) 2012-10-30 2020-06-02 Suppremol Gmbh Vector encoding an Fc gamma receptor IIB protein and composition of the encoded protein
US10028998B2 (en) 2012-10-30 2018-07-24 Suppremol Gmbh Method for treating an inflammatory disease and/or an autoimmune disease with a soluble FcγRIIb
EP2796144A1 (en) * 2013-04-26 2014-10-29 SuppreMol GmbH Highly concentrated Formulations of soluble Fc receptors
EP2837637A1 (en) 2013-08-16 2015-02-18 SuppreMol GmbH Novel anti-FcyRIIB IgG-type antibody
CA2927263C (en) 2013-10-16 2022-12-13 Suppremol Gmbh Soluble fc gamma receptor for treatment of autoimmune bullous diseases
JP6710451B2 (ja) * 2016-03-31 2020-06-17 東ソー株式会社 改変型組換えFcγRIIb
WO2020002252A1 (de) * 2018-06-25 2020-01-02 Basf Coatings Gmbh Verfahren zur herstellung einer optimierten beschichtung und mittels dieses verfahrens erhältliche beschichtung
CN111454914A (zh) * 2019-01-18 2020-07-28 嘉兴安宇生物科技有限公司 一种腺病毒快速纯化方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69434447T2 (de) 1993-06-07 2006-05-18 Vical, Inc., San Diego Für die gentherapie verwendbare plasmide
CA2225460A1 (en) 1995-06-23 1997-01-09 Winston Campbell Patterson Transcriptional regulation of genes encoding vascular endothelial growth factor receptors
US6849719B2 (en) 1997-09-17 2005-02-01 Human Genome Sciences, Inc. Antibody to an IL-17 receptor like protein
EP1006183A1 (en) 1998-12-03 2000-06-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Recombinant soluble Fc receptors
DE10157290A1 (de) * 2001-11-22 2003-06-05 Max Planck Gesellschaft Pharmazeutische Zusammensetzung enthaltend sFcRgamma IIb oder sFcRgamma III
US20040132101A1 (en) * 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
ES2371468T3 (es) 2003-11-26 2012-01-03 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. SUSTANCIA QUE SE UNE AL RECEPTOR HUMANO llb MEDIANTE Fc DE IgG (Fc? Rllb).
DE602006020333D1 (de) 2005-12-13 2011-04-07 Suppremol Gmbh Multimere fc-rezeptor-polypeptide
EP1870442A1 (en) * 2006-06-19 2007-12-26 DSMIP Assets B.V. Air drying resin and composition
EP1870422A1 (en) 2006-06-20 2007-12-26 SuppreMol GmbH Means for the treatment of diseases characterized by an excessive immune reaction
JP2011526154A (ja) 2008-06-27 2011-10-06 ザイモジェネティクス, インコーポレイテッド 可溶性ハイブリッドFcγレセプターおよび関連する方法
US10669324B2 (en) 2012-10-30 2020-06-02 Suppremol Gmbh Vector encoding an Fc gamma receptor IIB protein and composition of the encoded protein
US10028998B2 (en) 2012-10-30 2018-07-24 Suppremol Gmbh Method for treating an inflammatory disease and/or an autoimmune disease with a soluble FcγRIIb

Also Published As

Publication number Publication date
PH12015500771A1 (en) 2015-06-08
RS56075B1 (sr) 2017-10-31
ES2628049T3 (es) 2017-08-01
KR102170674B1 (ko) 2020-10-28
DK2914624T3 (en) 2017-06-26
EP2914624A1 (en) 2015-09-09
JP2016503289A (ja) 2016-02-04
IL238528A0 (en) 2015-06-30
HRP20170894T1 (hr) 2017-09-08
CN104918955B (zh) 2018-10-09
WO2014068012A1 (en) 2014-05-08
EA033437B9 (ru) 2020-03-19
PH12015500771B1 (en) 2015-06-08
IL238528A (en) 2017-07-31
PL2914624T3 (pl) 2017-09-29
SG11201502749VA (en) 2015-05-28
AU2013340831A1 (en) 2015-04-30
KR20150122621A (ko) 2015-11-02
HK1209765A1 (en) 2016-04-08
BR112015008815A2 (pt) 2017-11-21
EA033437B1 (ru) 2019-10-31
IN2015DN03206A (es) 2015-10-02
EA201590845A1 (ru) 2015-08-31
US10028998B2 (en) 2018-07-24
US20140120080A1 (en) 2014-05-01
AU2013340831B2 (en) 2017-11-23
JP2018186833A (ja) 2018-11-29
EP2914624B1 (en) 2017-03-15
MX359802B (es) 2018-10-10
CL2015001127A1 (es) 2015-12-18
MY173686A (en) 2020-02-15
CA2887164C (en) 2020-12-29
SI2914624T1 (sl) 2017-07-31
JP6423351B2 (ja) 2018-11-14
CN104918955A (zh) 2015-09-16
CA2887164A1 (en) 2014-05-08
LT2914624T (lt) 2017-06-26
PT2914624T (pt) 2017-06-07
NZ706884A (en) 2019-05-31
HUE032786T2 (en) 2017-10-30

Similar Documents

Publication Publication Date Title
PH12015500771A1 (en) Novel fc gamma receptor iib variants
NZ731571A (en) T cell receptors
MX337985B (es) Polipeptidos que tienen actividad de celobiohidrolasa y polinucleotidos que codifican los mismos.
IN2014CN04586A (es)
MX337919B (es) Polipeptidos que tienen actividad de celobiohidrolasa y polinucleotidos que codifican los mismos.
MX2015008446A (es) Composiciones de proteinas de union multivalentes.
MY162737A (en) 4-1bb binding molecules
MX337984B (es) Variantes de alfa amilasa y polinucleotidos que codifican la misma.
MX337913B (es) Polipeptidos que tienen actividad celobiohidrolasa y polinucleotidos que codifican los mismos.
MX355356B (es) Variantes de alfa-amilasa y polinucleotidos que codifican las mismas.
MX2013004892A (es) Polipeptidos que tienen actividad de fosfolipasa c y polinucleotidos que codifican los mismos.
MX2015000312A (es) Polipeptidos que tienen actividad lipasa y polinucleotidos que los codifican.
MX2014004539A (es) Variantes de alfa-amilasa y polinucleotidos que codifican las mismas.
WO2013119302A3 (en) Gh61 polypeptide variants and polynucleotides encoding same
MX349517B (es) Polipeptidos que tienen actividad de proteasa y polinucleotidos que codifican los mismos.
MX358963B (es) Polipeptidos con actividad proteasa.
WO2013163590A3 (en) Gh61 polypeptide variants and polynucleotides encoding same
MX2014001594A (es) Polipeptidos que tienen actividad de celulasa y polinucleotidos que los codifican.
MX2017007105A (es) Variantes de lipasa y polinucleotidos que las codifican.
WO2012136898A3 (en) Novel cutinases, their production and uses
MX2014003403A (es) Polipeptidos que poseen actividad proteasa y polinucleotidos que los codifican.
MX363360B (es) Polipéptidos que poseen actividad proteasa y polinucleótidos que los codifican.
MX351284B (es) Polipeptidos con actividad proteasa.
WO2012030858A3 (en) Polypeptides having hemicellulolytic activity and polynucleotides encoding same
WO2013079531A3 (en) Polypeptides having peroxygenase activity and polynucleotides encoding same

Legal Events

Date Code Title Description
FG Grant or registration